The Karmanos Cancer Institute requests funds for five Staff Investigators. These five individuals link investigators from different Programs to focus on specific translational areas of research and education and mentoring. The mentorship role of senior investigators is of particular importance in aiding the growth of young scientists. Four of these Staff Investigators provide invaluable mentorship for selected Research Teams. Dr. Shirish Gadgeel (Developmental Therapeutics) is Co-Leader of the Lung Cancer Research Team. Dr. Elisabeth Heath (Developmental Therapeutics) is Leader of the Prostate Cancer Research Team. Dr. Lawrence Lum (Breast Cancer Biology joint with Developmental Therapeutics) is Co-Leader of the Tumor Immunology Research Team. Dr. Larry Matherly (Developmental Therapeutics) is Co-Leader of the Leukemia/Lymphoma Research Team and also leads our Cancer Biology Graduate Program. These four Research Team leaders coordinate research efforts and organize meetings. They encourage inter- and intra-programmatic collaborations with the goal of identifying opportunities for program projects and imminent translation to patient care. They partner with Program Leaders and Research Administration to learn of opportunities for seed funding and pilot projects and integrate these opportunities into the activities and priorities of their respective Research Teams. Infrastructure support, such as IT requirements and meeting preparation, are coordinated by these team leaders. Dr. Avraham Raz (Proteases and Cancer) is proposed as a Staff Investigator in light of his extensive experience and exceptional success in mentoring and advising young and established scientists. In particular, he fosters, advises, mentors, and directs junior scientists toward obtaining independent and collaborative funding. Funding for each of these Staff Investigators is requested at 10% effort.
; Five scientists have been selected to serve as Staff Investigators. Four of these Leaders are chosen to support their activities on their respective Research Teams. The fifth scientist is proposed to support his mentoring and advising activities on behalf of junior scientists.
|Hamel, Lauren M; Penner, Louis A; Albrecht, Terrance L et al. (2016) Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer. Cancer Control 23:327-337|
|Xie, Yuran; Kim, Na Hyung; Nadithe, Venkatareddy et al. (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120-9|
|Cheriyan, Vino T; Muthu, Magesh; Patel, Ketan et al. (2016) CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. Oncotarget :|
|Moorman, Patricia G; Alberg, Anthony J; Bandera, Elisa V et al. (2016) Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol 26:654-62|
|Najor, Nicole A; Weatherford, Layne; Brush, George S (2016) Prevention of DNA Rereplication Through a Meiotic Recombination Checkpoint Response. G3 (Bethesda) 6:3869-3881|
|Herroon, Mackenzie Katheryn; Diedrich, Jonathan Driscoll; Podgorski, Izabela (2016) New 3D-Culture Approaches to Study Interactions of Bone Marrow Adipocytes with Metastatic Prostate Cancer Cells. Front Endocrinol (Lausanne) 7:84|
|Gimotty, Phyllis A; Shore, Ronald; Lozon, Nancy L et al. (2016) Miscoding of Melanoma Thickness in SEER: Research and Clinical Implications. J Invest Dermatol 136:2168-2172|
|Ekanger, Levi A; Polin, Lisa A; Shen, Yimin et al. (2016) Evaluation of Eu(II) -based positive contrast enhancement after intravenous, intraperitoneal, and subcutaneous injections. Contrast Media Mol Imaging 11:299-303|
|Divi, Vasu; Harris, Jonathan; Harari, Paul M et al. (2016) Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234). Cancer :|
|Katz, Matthew H G; Shi, Qian; Ahmad, Syed A et al. (2016) Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 151:e161137|
Showing the most recent 10 out of 634 publications